Ofirnoflast clinical trials
Also written HT-6184.
How each study uses ofirnoflast is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ofirnoflast studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Halia Therapeutics, Inc. (5)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses ofirnoflast is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study to Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Red Blood Cell TransfusionsNot yet recruitingPhase 2Halia Therapeutics, Inc.NCT07738510Written as Ofirnoflast
- A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and AnemiaCompletedPhase 2Halia Therapeutics, Inc.NCT07052006Written as HT-6184
- A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DMWithdrawnPhase 2Halia Therapeutics, Inc.NCT07172867Written as HT-6184
- Evaluating Ability of HT-6184 to Reduce Inflammation and Pain After Third Molar ExtractionCompletedPhase 2Halia Therapeutics, Inc.NCT06241742Written as HT-6184
- Study to Evaluate HT-6184 in Healthy SubjectsCompletedPhase 1Halia Therapeutics, Inc.NCT05447546Written as HT-6184
Codes
What other systems call ofirnoflast · ClinicalTrials.gg INT014997
- UNII (FDA) 54PY2PBN7SOFIRNOFLASTOne source FDA
- NCI Thesaurus C206955OfirnoflastOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 54PY2PBN7S | OFIRNOFLAST | One source FDA |
| NCI Thesaurus | C206955 | Ofirnoflast | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.